HBV-related end-stage liver disease, such as decompensated cirrhosis and hepatocellular carcinoma (HCC), represents a growing cause of morbidity and mortality, notably in patients with low CD4+T-cell counts and high HBV DNA levels[3]. Here, CD4 is linked to hepatocellular carcinoma.